Drug Profile
Antisense HIV-1 therapy - Enzo Therapeutics
Alternative Names: HGTV-43; StealthVector®HGTV43™Latest Information Update: 15 Apr 2021
Price :
$50
*
At a glance
- Originator Enzo Therapeutics
- Class Antisense oligonucleotides; Antivirals; Gene therapies; Stem cell therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 15 Apr 2021 Antisense HIV-1 therapy is still in phase II trials for HIV-1 infections in USA (Parenteral) (Enzo Biochem pipeline, April 2021)
- 09 Sep 2016 Phase-II clinical trials in HIV-1 infections in USA (Parenteral) before September 2016 (Enzo Biochem pipeline, September 2016)
- 07 Jan 2016 Phase-I/II development for HIV-1 infections is ongoing in USA